Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review

Alzghari, Saeed K; Acuña, Valerie S.

doi:10.1016/j.jcv.2020.104380

Cited by 139 publications

(134 citation statements)

References 14 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Experimental therapies have been used since the outbreak of the COVID-19 pandemic and expert societies guided to enroll patients in clinical studies when possible, as no standard treatment exists so far. Although other drugs have been tested, the only potential supportive treatment for COVID-19 appears to be an IL-6 inhibitor, tocilizumab (17).…”

Section: Discussionmentioning

confidence: 99%

Early results of COVID-19 pneumonia cases treated with Ultra-Low doses of Radiotherapy (ULTRA-COVID study)

Moreno-Olmedo¹,

Suarez-Gironzini²,

Pérez³

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction:Since the outbreak of COVID-19 pandemic, healthcare system has focused its effort to find a treatment to avoid the fatal outcome of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Benefits and risks of systemic treatments are unclear. Radiotherapy could play a role in reducing the inflammatory response in the lungs and relieve life-threatening symptomsMethods:We designed a prospective study of Ultra-Low-Doses of Therapy with Radiation Applied to COVID-19 (ULTRA-COVID) for patients that are no candidates for invasive mechanical ventilation and show no improvement with medical therapy. (ClinicalTrials.gov Identifier: NCT04394182)Results:We present the preliminary results of two patients diagnosed with COVID-19 pneumonia treated with ULTRA-COVID. Significant clinical response is accompanied by lower radiological one, both have happened, achieving hospital discharge after 1 radiotherapy session over a period of 8 and 14 days, respectively.Conclusion:Preliminary clinical and radiological results suggest a potential benefit of treating COVID-19 pneumonia with ultra-LDRT.

show abstract

Section: Discussionmentioning

confidence: 99%

Early results of COVID-19 pneumonia cases treated with Ultra-Low doses of Radiotherapy (ULTRA-COVID study)

Moreno-Olmedo¹,

Suarez-Gironzini²,

Pérez³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Most of them focused on a certain specific subfields of COVID-19 research, such as drug therapy, diagnostic methods, or clinical symptoms. For example, Alzghari et al [ 2 ] performed a systematic review to investigate the effect of Tocilizumab on COVID-19, and Zhu et al [ 3 ] systematically reviewed the CT imaging features of COVID-19 to provide reference for clinical practice. The second kind is the bibliometric analysis which uses quantitative analysis methods to describe literature in a particular research domain.…”

Section: Introductionmentioning

confidence: 99%

The COVID-19 research landscape

Wang

Hong

2020

Medicine

View full text Add to dashboard Cite

Objectives: The Coronavirus Disease 2019 (COVID-19) caused heavy burdens and brought tremendous challenges to global public health. This study aimed to investigate collaboration relationships, research topics, and research trends on COVID-19 using scientific literature. Method: COVID-19-related articles published from January 1 to July 1, 2020 were retrieved from PubMed database. A total of 27,370 articles were included. Excel 2010, Medical Text Indexer (MTI), VOSviewer, and D3.js were used to summarize bibliometric features. Results: The number of the COVID-19 research publications has been continuously increasing after its break. United States was the most productive and active country for COVID-19 research, with the largest number of publications and collaboration relationships. Huazhong University of Science and Technology from China was the most productive institute on the number of publications, and University of Toronto from Canada ranked as Top 1 institute for global research collaboration. Four key research topics were identified, of which the topic of epidemiology and public health interventions has gathered highest attentions. Topic of virus infection and immunity has been more focused during the early stage of COVID-19 outbreak compared with later stage. The topic popularity of clinical symptoms and diagnosis has been steady. Conclusions: Our topic analysis results revealed that the study of drug treatment was insufficient. To achieve critical breakthroughs of this research area, more interdisciplinary, multi-institutional, and global research collaborations are needed.

show abstract

“…[8]. Limited observational studies have demonstrated tocilizumab to be associated with improvements in in ammatory markers, clinical response, and survival [9][10][11][12][13][14][15][16]. During an unprecedented time when proven effective therapies remain lacking, we aimed to describe our experience using off-label tocilizumab for COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Effects of Tocilizumab in COVID-19 patients: a cohort study

DeRonde

Vega

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, it has been proposed that tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure. Methods A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. Results Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1–21) after initial symptoms and 2 days (range 0–12) after hospital admission. On the day of administration, the median PaO2/FiO2 was 166 (range 33–523) and 50 patients (83.3%) had ARDS. By day 30, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. There was an increase in PaO2/FiO2 and an initial reduction in CRP that was not sustained beyond day 10. Conclusions Majority of patients demonstrated clinical improvement and were successfully discharged from the hospital alive after receiving tocilizumab. Similar to previous studies, infectious complications were not uncommon. A rebound effect with CRP was observed, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the treatment of COVID-19, however randomized controlled studies are urgently needed.

show abstract

Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review

Cited by 139 publications

References 14 publications

Early results of COVID-19 pneumonia cases treated with Ultra-Low doses of Radiotherapy (ULTRA-COVID study)

Early results of COVID-19 pneumonia cases treated with Ultra-Low doses of Radiotherapy (ULTRA-COVID study)

The COVID-19 research landscape

Effects of Tocilizumab in COVID-19 patients: a cohort study

Contact Info

Product

Resources

About